scholarly journals Botulinum Toxin Is Effective in the Management of Neurogenic Dysphagia. Clinical-Electrophysiological Findings and Tips on Safety in Different Neurological Disorders

2017 ◽  
Vol 8 ◽  
Author(s):  
Enrico Alfonsi ◽  
Domenico A. Restivo ◽  
Giuseppe Cosentino ◽  
Roberto De Icco ◽  
Giulia Bertino ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Neurological Disorders ◽  
Neurogenic Dysphagia ◽  
Electrophysiological Findings

scholarly journals Botulinum Toxin in Movement Disorders: An Update

Toxins ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 42
Author(s):  
Charenya Anandan ◽  
Joseph Jankovic
Keyword(s):  
Botulinum Toxin ◽  
Movement Disorders ◽  
Neurological Disorders ◽  
Active Drug ◽  
Therapeutic Agents ◽  
Therapeutic Modality ◽  
Review Of The Literature ◽  
Pilot Studies ◽  
The Us ◽  
Novel Applications

Since its initial approval in 1989 by the US Food and Drug Administration for the treatment of blepharospasm and other facial spasms, botulinum toxin (BoNT) has evolved into a therapeutic modality for a variety of neurological and non-neurological disorders. With respect to neurologic movement disorders, BoNT has been reported to be effective for the treatment of dystonia, bruxism, tremors, tics, myoclonus, restless legs syndrome, tardive dyskinesia, and a variety of symptoms associated with Parkinson’s disease. More recently, research with BoNT has expanded beyond its use as a powerful muscle relaxant and a peripherally active drug to its potential central nervous system applications in the treatment of neurodegenerative disorders. Although BoNT is the most potent biologic toxin, when it is administered by knowledgeable and experienced clinicians, it is one of the safest therapeutic agents in clinical use. The primary aim of this article is to provide an update on recent advances in BoNT research with a focus on novel applications in the treatment of movement disorders. This comprehensive review of the literature provides a critical review of evidence-based clinical trials and highlights recent innovative pilot studies.

Botulinum Toxin in the Treatment of Neurological Disorders

1994 ◽  
Vol 710 (1 Toxins and Ex) ◽  
pp. 76-87 ◽  
Author(s):  
MIRO DENIŠLIČ ◽  
ZVEZDAN PIRTOŠEK ◽  
DAVID B. VODUŠEK ◽  
JANEZ ZIDAR ◽  
DUŠKA MEH
Keyword(s):  
Botulinum Toxin ◽  
Neurological Disorders

scholarly journals Ultrasound guided injection of botulinum toxin into the salivary glands of children with neurological disorders

2016 ◽  
Vol 49 (2) ◽  
pp. 131-132 ◽  
Author(s):  
Marcia Wang Matsuoka ◽  
Sílvia Maria Sucena da Rocha ◽  
Lisa Suzuki ◽  
João Paulo Barnewitz ◽  
Rui Imamura ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Salivary Glands ◽  
Neurological Disorders ◽  
Ultrasound Guided

scholarly journals Botulinum Toxin A for Sialorrhoea Associated with Neurological Disorders: Evaluation of the Relationship between Effect of Treatment and the Number of Glands Treated

Toxins ◽  
2018 ◽  
Vol 10 (2) ◽  
pp. 55 ◽  
Author(s):  
Domenico Restivo ◽  
Mariangela Panebianco ◽  
Antonino Casabona ◽  
Sara Lanza ◽  
Rosario Marchese-Ragona ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Neurological Disorders ◽  
Botulinum Toxin A ◽  
Toxin A ◽  
Effect Of Treatment ◽  
The Relationship

scholarly journals Neurogenic Dysphagia: A Systematic Review and Proposal of a Classification System

Neurology ◽  
2020 ◽  
pp. 10.1212/WNL.0000000000011350
Author(s):  
Tobias Warnecke ◽  
Bendix Labeit ◽  
Jens Schroeder ◽  
Alexander Reckels ◽  
Sigrid Ahring ◽  
...  
Keyword(s):  
Neurological Disorders ◽  
Neurological Diseases ◽  
Underlying Disease ◽  
Qualitative Synthesis ◽  
Neurogenic Dysphagia ◽  
Stroke Patients ◽  
Chi Square ◽  
Brainstem Stroke ◽  
Unclear Etiology

Objective:Introduction and validation of a phenotypic classification of neurogenic dysphagia based on flexible endoscopic evaluation of swallowing (FEES).Methods:A systematic literature review was conducted, searching MEDLINE from inception to 05/2020 for FEES findings in neurological diseases of interest. Based on a retrospective analysis of FEES-videos in neurological diseases and considering the results from the review, a classification of neurogenic dysphagia was developed distinguishing different phenotypes. The classification was validated using 1012 randomly selected FEES-videos of patients with various neurological disorders. Chi-square-tests were used to compare the distribution of dysphagia phenotypes between the underlying neurological disorders.Results:159 articles were identified of which 59 were included in the qualitative synthesis. Seven dysphagia phenotypes were identified: (1) “Premature bolus spillage” and (2) “delayed swallowing reflex” occurred mainly in stroke patients, (3) “predominance of residue in the valleculae” was most common in Parkinson's disease, (4) “predominance of residue in the piriform sinus” occurred only in myositis, motoneuron disease and brainstem stroke patients, (5) “pharyngolaryngeal movement disorder” was found in atypical Parkinsonian syndromes and stroke patients, (6) “fatigable swallowing weakness” was common in patients with myasthenia gravis, and (7) “complex disorder” with a heterogeneous dysphagia pattern was the leading mechanism in amyotrophic later sclerosis. The interrater reliability showed a strong agreement (kappa = 0.84).Conclusion:Neurogenic dysphagia is not a mere symptom, but a multi-etiological syndrome with different phenotypic patterns depending on the underlying disease. Dysphagia phenotypes can facilitate differential diagnosis in patients with dysphagia of unclear etiology.

Sign in / Sign up

Export Citation Format

Share Document